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comparing antihypertensive regimens concluded that use of calcium-channel blockers and thiazide-type diuretics was associated with lower VVV of BP than use of angiotensinconverting enzyme inhibitors, angiotensin receptor blockers, or β-blockers. 10 One potential explanation for this finding is that antihypertensive medications with longer half-lives and less-pronounced BP rebound after missed doses may limit the influence of nonadherence on VVV of BP. 11 Accordingly, there may be an interaction between antihypertensive drug type and medication adherence on VVV of BP.
The goal of the current study was to determine the association between antihypertensive medication adherence and VVV of BP in ALLHAT. We evaluated the association, overall, and by ALLHAT randomization assignment to different antihypertensive drug classes. We also evaluated whether participants who had a change in adherence between 2 time periods had a change in VVV of BP. Finally, we conducted a mediation analysis to determine whether medication nonadherence explained the association between VVV of BP and cardiovascular and mortality outcomes. ALLHAT is well suited to answering these questions because the study included a large sample of treated individuals with hypertension who had repeated measures of medication adherence and BP and prospective follow-up for outcomes.
Methods
Details of ALLHAT have been described previously. 12, 13 Briefly, ALLHAT was a randomized, double-blind, multicenter trial to determine whether treatment with calcium-channel blockers, angiotensin-converting enzyme inhibitors, or α-adrenergic blockers, all newer antihypertensive classes at the time, was superior to treatment with a thiazide diuretic for lowering risk for fatal CHD or nonfatal myocardial infarction (MI). Participants were randomized to chlorthalidone, amlodipine, lisinopril, or doxazosin and treated to a goal systolic/diastolic BP of <140/90 mm Hg. All participants in ALLHAT provided written informed consent, and all centers received institutional review board approval.
Eligibility for the Current Analyses
The doxazosin arm in ALLHAT was stopped early because of a 25% higher incidence of cardiovascular events, including ≈2-fold higher risk of heart failure, accompanied by a very low probability of reaching a statistically significant difference in the primary end point. 14 Therefore, participants in this randomization arm were excluded from the current analyses. Also, the sample for the primary analyses was restricted to ALLHAT participants who attended and had BP and medication adherence data from at least 5 of the 7 study visits conducted 6 to 28 months after randomization. A minimum of 5 visits was chosen to ensure a robust assessment of VVV of BP. 15 Visits in the first 6 months after randomization were excluded because large reductions in BP occurred before this time point while participants were being titrated to achieve their goal BP, and this could have inflated estimates of VVV of BP. This approach is consistent with previous analyses of VVV of BP in ALLHAT. 9 The sample in analyses assessing the association between VVV of BP and outcomes was restricted to participants who had no outcome events (ie, no fatal CHD or nonfatal MI, stroke, all-cause mortality, and heart failure) before the 28-month study visit. In secondary analyses, we additionally required participants to have BP and medication adherence data from at least 5 of the 7 study visits conducted 32 to 56 months after randomization.
Measures

Antihypertensive Medication Adherence
Adherence to medication was assessed at each visit by a study clinician using the Adherence Survival Kit developed for ALLHAT. 16 Specifically, participants were asked whether they had taken at least 80% of their assigned study drug since the last follow-up visit. For our primary analyses, participants were categorized as nonadherent if they reported having taken <80% of their assigned antihypertensive medication at ≥1 visits during the 6-to 28-month time period after randomization. We also conducted secondary analyses in which participants were categorized as nonadherent if they reported having taken <80% of their assigned medication at ≥1 visits during the 32 to 56 months after randomization. In a sensitivity analysis, participants were categorized as nonadherent if they reported taking <80% of the prescribed antihypertensive medication at ≥2 visits during the 6 to 28 months postrandomization time period.
VVV of BP
VVV of BP was calculated during early (6-28 months after randomization) and, separately, late time periods (32-56 months after randomization) using 3 metrics based on each ALLHAT participant's BP measurements: standard deviation independent of mean (SDIM), SD, and average real variability ( Figure SI in the online-only Data Supplement). 3, 17 The BP used for these calculations was the mean of 2 measurements taken during each follow-up study visit according to a standardized BP measurement protocol. 12 Although we considered other VVV of BP metrics, the correlation between VVV of BP metrics is high, suggesting that analyses with additional metrics would not provide new information. 15 Our primary VVV of BP metric was SDIM.
Covariates
Covariates were selected a priori based on their potential to serve as confounders of the association between adherence and VVV of BP.
Covariates included sociodemographic characteristics, practice site characteristics, medical comorbidities, randomization assignment, BP at baseline and during follow-up, and BP medication prescribing before and after randomization.
Cardiovascular and Mortality Outcomes
Outcomes included fatal CHD or nonfatal MI, stroke, all-cause mortality, and heart failure. Details of the event ascertainment process are provided elsewhere. 12, 13 Participants were followed from the end of the VVV of BP assessment period to the date of each outcome, their date of death, or end of active ALLHAT follow-up (October 1, 2001 through March 31, 2002).
Statistical Analysis
Participant characteristics and SDIM of SBP were calculated for nonadherent and adherent participants separately. We used linear regression to calculate the adjusted mean difference in the SDIM of SBP in nonadherent versus adherent (reference group) participants. Three levels of adjustment were performed: (1) an initial model with adjustment for age, race/ethnicity, sex, geographic region of practice site, and practice type; (2) a second model with additional adjustment for estimated glomerular filtration rate, diabetes mellitus, body mass index, smoking status, history of MI or stroke, history of coronary revascularization, history of other atherosclerotic cardiovascular disease, major ST segment depression, left ventricular hypertrophy, baseline systolic and diastolic BP, use of BP medications before study randomization, and randomization assignment; and (3) a third model with further adjustment for covariates from follow-up visits, including mean SBP during follow-up, mean number of antihypertensive medications taken during months 6 to 28, change in antihypertensive medication regimen during follow-up, antihypertensive medication classes being taken, and statin use. The above analyses were repeated using SDIM of DBP and alternate metrics of VVV of SBP (ie, SD and average real variability) as the measure of VVV and after defining nonadherence as ≥2 visits with <80% adherence. As a further sensitivity analysis, the above analyses were repeated while restricting the analysis to participants who remained on a single drug class (ie, only the drug to which they were randomized) from month 6 to 28 of follow-up. The above analyses were also repeated stratified by antihypertensive drug class randomization assignment. We tested for effect modification between adherence and randomization drug class on VVV of BP in linear regression models with the full population and multiplicative by guest on October 27, 2017 http://hyper.ahajournals.org/ Downloaded from interaction terms between medication adherence and randomization assignment. In secondary analyses, we determined whether withinparticipant change in adherence between the early study period (6-28 months post randomization) and the late study period (32-56 months post randomization) was associated with their change in SDIM of SBP during this same interval. For this analysis, participants were grouped as being adherent in both the early and late study periods, nonadherent in both study periods, nonadherent in the early period but adherent in the late period, and adherent in the early time period but nonadherent in the late period. Mean change in SDIM of SBP between the early and late study periods was calculated for each of these groups.
In a final analysis, we assessed whether medication nonadherence explained the association between VVV of BP and major cardiovascular and mortality outcomes by considering 2 multivariable Cox proportional hazards regression models, one that assessed the hazard ratios for outcomes associated with VVV of BP without medication adherence and another with medication adherence included. 18 For these analyses, the parameter of interest was the difference in the estimated association of SDIM of SBP with outcomes between the 2 models, and the 95% confidence interval (CI) for this estimate was calculated using a 1000 iteration bootstrap. Data analyses were conducted in Stata Version 13 (Stata, Inc College Station, TX).
Results
Of the 33 357 participants randomized to chlorthalidone, amlodipine, or lisinopril in ALLHAT, 9353 were excluded because they had <5 visits with BP measured and an additional 4214 were excluded because they had <5 visits at which adherence was assessed. This left 19 970 participants meeting the eligibility criteria for our primary analyses. Fifteen percent of these participants (n=2912) were nonadherent. Compared with adherent participants, nonadherent participants were slightly older and more likely to be Hispanic or Black (Table  1) . Nonadherent participants were more likely to have evidence of end-organ damage as signified by major ST segment depression or T wave inversion or left ventricular hypertrophy on ECG but were less likely to have a history of MI, stroke, or coronary revascularization. They were also less likely to have used BP medications before randomization and less likely to use statins during follow-up. Nonadherent participants were also more likely to have changes in BP medication classes during follow-up, were more likely to have uncontrolled BP between 6 and 28 months after randomization, and had higher mean SBP and DBP at those visits. The association between nonadherence status and higher BP remained statistically significant in adjusted analyses (Table SII) .
SDIM of SBP was higher among nonadherent than among adherent participants (11.4±4.9 versus 10.5±4.5; P<0.001; Table 2 ). After full adjustment, nonadherent participants had 0.8 (95% CI, 0.7-1.0; P<0.001) higher SDIM of SBP than adherent participants. Also, compared with adherent participants, those who were nonadherent had higher SD and average real variability of SBP. This same pattern was present when restricting the sample to 11 290 participants without antihypertensive medication changes (Table SIII) . The association between adherence status and VVV of SBP was consistent across antihypertensive drug randomization assignment (P>0.8 for interaction term for all definitions of VVV of SBP; Table SIV ). Nonadherent participants also had higher VVV of DBP (Table SV) .
Overall, 4.6% of participants had ≥2 visits with <80% adherence. SDIM of SBP was higher among nonadherent participants versus adherent participants according to this more stringent categorization of nonadherence (11.0±4.6 versus 10.6±4.6; P=0.01). After full multivariable adjustment, SDIM of SBP was 0.5 (95% CI, 0.2-0.9; P=0.001) higher among nonadherent than among adherent participants (Table SVI) . The same pattern of results was found when using the other definitions of VVV of SBP and VVV of DBP (Table SVII) .
Participants who were nonadherent in both the early and late study periods had higher SDIMs of SBP than those who were adherent in both study periods (Table 3 ). There was minimal change in the SDIM of SBP between the early and late study periods for participants who were adherent in both study periods and nonadherent in both study periods. A substantial number of participants, however, had a change in adherence between the early and late study period with 6.5% switching from adherent to nonadherent and 10.0% switching from nonadherent to adherent. Compared with participants who were adherent in both time periods, participants who changed from adherent to nonadherent had an increase in SDIM of SBP (0.9; 95% CI, 0.5-1.3; P<0.001), whereas participants who changed from nonadherent to adherent had a decrease in SDIM of SBP (−0.7; 95% CI, −1.0 to −0.3; P<0.001).
Among participants in the primary analysis without a cardiovascular event before the 28-month visit (n=18 442), being in the highest versus lowest quintile of SDIM of SBP was associated with increased risk of fatal CHD or nonfatal MI, stroke, heart failure, and all-cause mortality after multivariable adjustment (Table 4) . In a mediation analysis, further adjustment for adherence status did not explain the association between SDIM of SBP and any of our cardiovascular or mortality outcomes.
Discussion
In this post hoc analysis of ALLHAT data, self-reported medication nonadherence was associated with higher VVV of BP. These results were consistent for VVV of SBP, VVV of DBP, for 3 commonly used metrics of VVV of BP, remained present after adjustment for differences in participant characteristics, and were consistent for participants randomized to chlorthalidone, amlodipine, and lisinopril. Change in adherence was associated with change in VVV of BP, further supporting an association between antihypertensive medication nonadherence and higher VVV of BP. Although there was a statistically significant association between medication nonadherence and VVV of BP, nonadherence did not explain the association between VVV of BP and cardiovascular and mortality outcomes.
The finding that antihypertensive medication adherence was associated with VVV of BP is consistent with 2 previous studies. The first study involved a sample of 1391 patients taking antihypertensive medication enrolled in a Medicare managed care program. 19 In that study, SDIM of SBP was 1.2 U higher in nonadherent than in adherent patients. That study was restricted to BP measurements abstracted from patient charts; BP was not measured using a standardized protocol. The second study assessed the association between adherence and VVV of BP in the African American Study of Kidney Disease and Hypertension (AASK) Trial. 20 Among 988 participants with established chronic kidney disease in AASK, self-reported and pill count measures of nonadherence were associated with higher VVV of BP.
The current study extends these previous findings in several ways. ALLHAT includes a racially diverse population and, hence, increases the generalizability of the finding that nonadherence is associated with increased VVV of BP. The current study also shows that individuals who changed their adherence to BP medications had changes in their VVV of BP. This suggests that consistent use of BP medications may reduce VVV of BP. Third, the current study shows that the association between adherence and VVV of BP is independent of drug type and accordingly that differences in the effects of ALLHAT indicates Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; BP, blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; LVH, left ventricular hypertrophy; SBP, systolic blood pressure; and VVV, visit-to-visit variability.
*Eligibility criteria for primary analyses in the current study included availability of blood pressure and medication adherence data from at least 5 of the 7 study visits conducted between 6 and 28 mo post randomization. †Adherent participants reported taking >80% of all antihypertensive medication at all study visits in early time period (study visits from month 6 to 28).
‡Nonadherent participants reported taking <80% of antihypertensive medication at ≥1 study visits during same time period. §Uncontrolled BP defined by mean SBP ≥140 mm Hg and mean DBP ≥ 90 mm Hg between study visits from month 6 to 28.
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http://hyper.ahajournals.org/ Downloaded from nonadherence to specific antihypertensive medications on BP may not be a substantial factor related to VVV of BP. Although the current study confirmed that VVV of BP is associated with cardiovascular outcomes and mortality, it also demonstrated that nonadherence was not a mediator of this association. Thus, improving adherence is unlikely to offset the increased risk associated with VVV of BP found in treated patients with hypertension. VVV of BP has been associated with adverse prognosis in both treated and untreated patients with hypertension. 2, 5 Given the lack of mediation, other pathways are likely to underlie the adverse influence of VVV of BP on outcomes in both patient groups. 21 Small experimental studies suggest that large fluctuations in BP are associated with endothelial injury and end-organ damage. 22 There is a need for additional studies to elucidate the mechanisms underlying VVV of BP and its effect on cardiovascular outcomes.
The current findings should be interpreted in the context of several limitations. First, adherence was assessed using a selfreport rather than an objective measure. Previous studies comparing self-reported adherence with electronic or biochemical (blood and urine assays for drugs and metabolites) measures of adherence have demonstrated that individuals over-report their adherence. [23] [24] [25] Accordingly, estimates of the prevalence and frequency of nonadherence may be conservative. However, nonadherence on this measure maintained strong associations with higher SBP, higher DBP, and uncontrolled BP. Furthermore, selfreported adherence has been correlated with objective measures including pill count, pharmacy fill rates, and electronic monitoring. 26 These data suggest that the adherence measure used in ALLHAT was valid. To our knowledge, there are no large studies with repeated measures of BP and cardiovascular prognosis that have data on electronically measured adherence to antihypertensive medication. In this context, reliance on self-reported measures of adherence, although imperfect, is the best available option for studying whether nonadherence is a mediator of the association between VVV of BP and prognosis among individuals with medication-treated hypertension. We did not assess dayto-day changes in adherence to antihypertensive medications; adherence is a dynamic process in many patients, and variability in adherence may be more robustly associated with VVV of BP than the summary classification of adherence used in this study. As with all randomized trials, participants may not be representative of the general population. ALLHAT, however, was a large simple trial that attempted to replicate real-world practice, and the physiology of VVV of BP is unlikely to be different in ALLHAT compared with the general population. Participants' BP was closely monitored, and medications were carefully titrated to achieve and maintain SBP/DBP <140/90 mm Hg during follow-up. This may have reduced the extent of VVV of BP in the sample. Estimates of SDIM were derived from the distribution of BP in ALLHAT, and therefore, caution should be applied in generalizing the current results to other populations. A substantial number of participants were excluded from these analyses because they had <5 visits with assessment of antihypertensive medication adherence. The association of VVV of BP with fatal CHD or nonfatal MI, stroke, and all-cause mortality was similar in the current study as previously reported in ALLHAT. 20 Although VVV of BP was associated with a larger hazard ratio for heart failure after excluding people with <5 visits with assessment of adherence, an increased risk for heart failure was present in both the current and previous analyses.
Perspectives
Results from the current study suggest that antihypertensive medication nonadherence contributes to VVV of BP and that efforts to reduce nonadherence have the potential to decrease VVV of BP. The difference in the VVV of BP attributable to nonadherence was similar to or greater than the difference observed between various types of antihypertensive drug classes. 9, 10, 27, 28 However, nonadherence did not mediate the association between higher VVV of BP and increased risk for CVD outcomes. CI indicates confidence interval; MI, myocardial infarction; and VVV of SBP, visit-to-visit variability of systolic blood pressure.
*Adherent participants reported taking >80% of all antihypertensive medication at all study visits in early time period (study visits from month 6 to 28). †Nonadherent participants reported taking <80% of antihypertensive medication at ≥1 study visits during same time period. ‡Model 1 includes adjustment for age, race/ethnicity, sex, geographic region of practice site, and practice type. §Model 2 includes variables in model 1 and body mass index, smoking status, estimated glomerular filtration rate, diabetes mellitus, history of MI or stroke, history of coronary revascularization, history of other atherosclerotic cardiovascular disease, major ST depression, left ventricular hypertrophy, baseline SBP and diastolic blood pressure, use of blood pressure medications before study randomization, and randomization assignment (chlorthalidone, amlodipine, or lisinopril).
║Model 3 includes variables in model 2 and the following variables measured during study visits conducted between 6 and 28 mo post randomization: mean systolic blood pressure, antihypertensive medication classes taken beyond the primary randomized drug, mean number of hypertension medications prescribed, change in antihypertensive medication regimen, and statin use. Further work is needed to examine both the mechanisms underlying the association between VVV of BP and CVD outcomes and whether decreasing VVV of BP can improve outcomes.
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Model 3 includes variables in model 2 and the following variables measured during study visits conducted between 6 and 28 months post-randomization: antihypertensive medication classes taken beyond the primary randomized drug, mean number of hypertension medications prescribed, change in antihypertensive medication regimen, and statin use. VVV of SBP, visit-to-visit variability of systolic blood pressure; SD, standard deviation *Adherent participants reported taking more than 80% of all antihypertensive medication at all study visits in early time period (study visits from month 6 to 28) † Nonadherent participants reported taking less than 80% of antihypertensive medication at one or more study visits during same time period. ‡ Model 1 includes adjustment for age, race/ethnicity, gender, geographic region of practice site, and practice type. § Model 2 includes variables in model 1 and body mass index, smoking status, estimated glomerular filtration rate, diabetes, history of MI or stroke, history of coronary revascularization, history of other atherosclerotic cardiovascular disease, major ST depression or T wave inversion, left ventricular hypertrophy, baseline systolic and diastolic blood pressure, use of blood pressure medications prior to study randomization. Abbreviations: SBP, systolic blood pressure; SD, standard deviation *Adherent is defined as taking more than 80% of all antihypertensive medication at all study visits in early time period (study visits from month 6 to 28); nonadherent defined as one or more study visits taking less than 80% of antihypertensive medication during same time period. † Model 1 includes adjustment for age, race/ethnicity, gender, geographic region of practice site, and practice type. ‡ Model 2 includes variables in model 1 and body mass index, smoking status, estimated glomerular filtration rate, diabetes, history of MI or stroke, history of coronary revascularization, history of other atherosclerotic cardiovascular disease, major ST depression or T wave inversion, left ventricular hypertrophy, baseline systolic and diastolic blood pressure, use of blood pressure medications prior to study randomization. § Model 3 includes variables in model 2 and the following variables measured during the VVV of BP assessment period: mean systolic blood pressure, antihypertensive medication classes taken (beyond the primary randomized drug), mean number of hypertension medications prescribed, changes in antihypertensive medication, and statin use. .001 Abbreviations: DBP, diastolic blood pressure; SD, standard deviation *Adherent is defined as taking more than 80% of all antihypertensive medication at all study visits in early time period (study visits from month 6 to 28) † Nonadherent defined as one or more study visits taking less than 80% of antihypertensive medication during same time period. ‡ Model 1 includes adjustment for age, race/ethnicity, gender, geographic region of practice site, and practice type. § Model 2 includes variables in model 1 and body mass index, smoking status, estimated glomerular filtration rate, diabetes, history of MI or stroke, history of coronary revascularization, history of other atherosclerotic cardiovascular disease, major ST depression, left ventricular hypertrophy, baseline systolic and diastolic blood pressure, use of blood pressure medications prior to study randomization and randomization assignment (chlorthalidone, amlodipine, or lisinopril). 2) <0.001 Abbreviations: SBP, systolic blood pressure; SD, standard deviation *Adherent is defined as taking more than 80% of all antihypertensive medication at less than 2 study visits in early time period (study visits from month 6 to 28) † Nonadherent defined as two or more study visits taking less than 80% of antihypertensive medication during same time period. ‡ Model 1 includes adjustment for age, race/ethnicity, gender, geographic region of practice site, and practice type. § Model 2 includes variables in model 1 and body mass index, smoking status, estimated glomerular filtration rate, diabetes, history of MI or stroke, history of coronary revascularization, history of other atherosclerotic cardiovascular disease, major ST depression, left ventricular hypertrophy, baseline systolic and diastolic blood pressure, use of blood pressure medications prior to study randomization and randomization assignment (chlorthalidone, amlodipine, or lisinopril). 0.4 (0.2, 0.6) <0.001 Abbreviation: DBP, diastolic blood pressure; SD, standard deviation *Adherent is defined as taking more than 80% of all antihypertensive medication at less than 2 study visits in early time period (study visits from month 6 to 28) † Nonadherent defined as two or more study visits taking less than 80% of antihypertensive medication during same time period. ‡ Model 1 includes adjustment for age, race/ethnicity and gender. § Model 2 includes variables in model 1 and estimated glomerular filtration rate, diabetes, history of MI or stroke, history of coronary revascularization, history of other atherosclerotic cardiovascular disease, major ST depression or T wave inversion, left ventricular hypertrophy, baseline systolic and diastolic blood pressure, use of blood pressure medications prior to study randomization and randomization assignment (chlorthalidone, amlodipine, or lisinopril).
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